产品名称：Stemgent/Oct4 (POUF5F1) Antibody | Pluripotency Marker/09-0023/100 μl

产品编号：09-0023

市场价：¥0.00

场地：美国(厂家直采)

产品分类：抗体类>一抗>功能性抗体>

联系QQ：1570468124

电话号码：4000-520-616

邮箱： info@ebiomall.com

美元价：待定

品牌： Stemgent

公司：Stemgent, Inc

公司分类：

商品介绍

ImmunocytochemistryanalysisofOct4onH1humanEScells.CellsweretreatedwithOct4Antibody(AffinityPurified)usinga1:100dilutionfollowedbyasecondaryCy™3conjugatedantibody(red).DAPIstainingwasperformedtovisualizenuclei(blue).

FlowcytometryanalysisofOct4onH1humanEScells.PurplehistogramrepresentsOct4Antibodyandopenhistogramrepresentsisotypecontrolatthesameconcentration.

ProductOverview

Oct4(Octamer-4,alsoknownasPOU5F1)isahomeodomaintranscriptionfactorofthePOUfamilywhichisinvolvedintheregulationofpluripotencyduringnormaldevelopment.TheexpressionofOct4isassociatedwithanundifferentiatedphenotypeinembryonicstem(ES)cells,whilegeneknockdownofOct4promotesdifferentiation.Assuch,itisfrequentlyusedasaMarkerforundifferentiatedEScellsorinducedpluripotentstem(iPS)cells.Oct4isoneofthekeytranscriptionfactorsusedtoreprogrammouseandhumanfibroblaststoapluripotentstate.TheOct4Antibody(AffinityPurified)wasscreenedonhumanandmouseEScellsusingimmunocytochemistryandflowcytometryandselectedasthebestOct4antibodyavailableforresearchersneedingtodemonstratepluripotency.

ProductSpecifications

Size

100μl

Clone

Polyclonal

Isotype

RabbitIgG

Immunogen

SyntheticpeptideconjugatedtoKLHderivedfromwithinresidues300totheC-terminusofhumanOct4

Reactivity

Mouse,Human

Preparation

Theantibodywaspurifiedbyimmunogenaffinitychromatography.

Formulation

Phosphate-bufferedsolution,pH7.4,1%BSAand0.02%sodiumazide

StorageandStABIlity

Storeat4°Cprotectedfromlight.Donotfreeze.Stablefor6monthsfromdateofreceiptwhenstoredasdirected.

QualityControl

Testedbyimmunocytochemistryandflowcytometrytoensureproductquality.

RecommendedUsage

Thesuggesteduseofthisantibodyisa1:100dilutionforimmunocytochemistryanda1:5dilutionforflowcytometry.Forapplicationspecificprotocols,pleasereferenceProtocol:ImmunocytochemistryandProtocol:FlowCytometryonlineatwww.Stemgent.com/support/protocols.

SpecificationSheets

09-0023SpecificationsSheet

SafetyDataSheets

09-0023SafetyDataSheet

Protocols

Protocol:ImmunoflourescenceStainingofCellsforFlowCytometry
Protocol:Immunocytochemistry

RelatedProducts

mRNAReprogrammingKit(00-0071)
microRNABoosterKit(00-0073)

References

Looijenga,L.H.,Stoop,H.,deLeeuw,H.P.,deGouveiaBrazao,C.A.,Gillis,A.J.,vanRoozendaal,K.E.,vanZoelen,E.J.,Weber,R.F.,Wolffenbuttel,K.P.,vanDekken,H.,Honecker,F.,Bokemeyer,C.,Perlman,E.J.,Schneider,D.T.,Kononen,J.,Sauter,G.,Oosterhuis,J.W.(2003)POU5F1(OCT3/4)identifiescellswithpluripotentpotentialinhumangermcelltumors.CancerRes63:2244-2250.
Zaehres,H.,Lensch,M.W.,Daheron,L.,Stewart,S.A.,Itskovitz-Eldor,J.,Daley,G.Q.(2005)High-efficiencyRNAinterferenceinhumanembryonicstemcells.StemCells23:299-305.
Takahashi,K.,andYamanaka,S.(2006).Inductionofpluripotentstemcellsfrommouseembryonicandadultfibroblastculturesbydefinedfactors.Cell126,663-676.
Takahashi,K.,TanabeK.,Ohnuki,M.,Narita,M.,IchisakaT.,TomodaK.andYamanaka,S.(2007)Inductionofpluripotentstemcellsfromadulthumanfibroblastsbydefinedfactors.Cell131:861-872.
Park,I.H.,Arora,N.,Huo,H.,Maherali,N.,Ahfeldt,T.,Shimamura,A.,Lensch,M.W.,Cowan,C.,Hochedlinger,K.,andDaley,G.Q.(2008)Disease-specificinducedpluripotentstemcells.Cell134:877-886.

AdditionalPublications

BurnettLC;LeDucCA;SulsonaCR;PaullD;EddiraS;LevyB;SallesJP;TauberM;DriscollDJ;EgliD;LeibelRL."Inducedpluripotentcells(iPSC)createdfromskinfibroblastaofpatientswithPrader-Willisyndrome(PWS)retainthemolecularsignatureofPWS."StemCellRes(2016),doi:10.1016/j.scr.2016.08.008
SridharA;OhlemacherSK;LangerKB;MeyerJS."RobustdifferentiationofmRNA-reprogrammedhumaninducedpluripotentstemcellstoardaretinallineage."StemCellTranslationalMedicine5:10(2016)
OhlemacherSK;SridharA;XiaoY;HochstetlerAE;SarfaraziM;CumminsTR;MeyerJS."Stepwisedifferentiationofretinalganglioncellsfromhumanpluripotentstemcellsenablesanalysisofglaucomatousneurodegeneration."StemCellsdoi:10.1002/stem.2356(2016)
PoleganovMA;EminliS;BeissertT;HerzS;MoonJ-I;GoldmannJ;BeyerA;HeckR;BurkhartI;RoldanDB;TureciO;YiK;HamiltonB;SahinU."Efficientreprogrammingofhumanfibroblastsandblood-derivedendothelialProgenitorcellsusingnonmodifiedRNAforreprogrammingandimmuneevasion."HumanGeneTherapy26:751(2015)
HanF;WangW;CHenB;CHenC;LISen;LuX;DuanJ;ZhangY;ZhangYA;GuoW;LiG."Humaninducedpluripotentstemcell-derivedneuronsimprovemotorasymmetryina6-hydroxydopamine-inducedratmodelofParkinson"sdisease."Cytotherapy17:665(2015)
PaullD;SevillaA;ZhouH;HahnAK;KimH;NapolitanoC;TsankovA;ShangL;KrumholzK;JagaseesanP;WoodardCM;SunB;VilbouxT;ZimmerM;ForeroE;MoroziewiczDN;MartinezH;MalicdanMCV;WeissKA;VensandLB;DusenberryCR;PolusH;SyKTL;KahlerDJ;GahlWA;SolomonSL;ChangS;MeissnerA;EgganK;NoggleSA."Automated,high-throughputderivation,characterizationanddifferentiationofinducedpluripotentstemcells."NaureMethods12:885(2015)
RenJ;BrionesV;BarbourS;YuW;HanY;TarashimaM;MueggeK."TheATPbindingsiteofthechromatinremodelinghomologLSHisrequiredfornucleosomedensityanddenovoDNAmethylationatrepeatsequences."NuclAcidsResdoi:10.1093/nar/gku1371(2015)

品牌介绍

Stemgent mRNA体细胞重编程系统

产品特点

1.快速 Fast

Stemgent® MicroRNA-Enhanced mRNA Reprogramming System只需2周即可将靶细胞重编程为iPS细胞，与仙台病毒（Sendai Virus）、非整合型DNA载体（Episomal DNA Vectors）等传统iPS重编程方法相比，缩短实验周期超过50%以上（Figure. 1）。

Figure 1. Stemgent® mRNA重编程系统、仙台病毒依赖的重编程系统以及游离型DNA载体依赖的重编程系统重编程时程比较。

简便 Easy

与病毒、DNA载体依赖的iPS重编程手段不同，使用Stemgent® MicroRNA-Enhanced mRNA Reprogramming System对靶细胞进行重编程，生成的iPS细胞无需进行复杂耗时的下游筛选程序，只需简简单单6个步骤，即可轻松构建iPS细胞系。

	Description	Day
Step 1	Material Preparation	Prior to starting
Step 2	Plate Cells	0
Step 3	Transfect Cells	1 to 12
Step 4	Identify Cells	13-14
Step 5	Pick and Passage iPS Cell Colonies	15-16
Step 6	Maintain iPS Cell Cultures	16+

注：因所用细胞类型及实验条件不同，上述时间轴可能略有不同，仅供参考。

Figure 2. Stemgent® MicroRNA-Enhanced mRNA Reprogramming System重编程过程时间表、显微镜下观察到的重编程过程中靶细胞形态变化。第12天，形成的iPS克隆表达多能型Marker TRA-1-81。

高效 Efficient

病毒、DNA载体等依赖的iPS重编程技术，其重编程效率介于0.00001%到1%之间不等，而Stemgent® MicroRNA-Enhanced mRNA Reprogramming System的重编程效率远远大于1%，极大地提高了iPS克隆的产出率。

表1. 不同类型iPS重编程手段效率比较

Reprogramming Method	Efficiency	Integrating	Screening
RNA	>1%	No	No
仙台病毒（Sendai virus）	0.01-1%	No	Yes
DNA载体（Episomal/Minicircle）	0.00%	Possible	Yes
慢病毒（Lentivirus）	0.001-0.01%	Yes	Yes
腺病毒（Adenovirus）	0.0001-0.001%	Possible	Yes
Protein	0.00%	No	No

安全 Safe

某些iPS研究领域，例如iPS临床研究、治疗应用等，对iPS细胞的安全性提出了极高的要求。使用Stemgent® MicroRNA-Enhanced mRNA Reprogramming System重编程靶细胞，无需担心构建的iPS细胞系可能含有病毒载体残留，亦无需担心无关的基因整合进宿主基因组，是目前适用于临床研究及治疗的最理想选择。

而以仙台病毒（Sendai Virus）为载体的iPS重编程手段，其病毒基因组虽然不会整合进宿主染色体，仙台病毒本身也不具备复制能力，但是为了构建真正意义上的virus-free的iPS细胞系，通常需要经过一个10-20代、耗时费力的筛选过程，以确保最终得到的iPS细胞系无病毒载体残留。以慢病毒（Lentivirus）体的iPS重编程手段，病毒基因组能够永久整合进宿主基因组，会给后续的iPS细胞分析带来干扰。